months. Morbidity (230o) and mortality (10%) were substantial, however, and this approach cannot be recommended as initial treatment for most patients.
By contrast, the least invasive method of management is thoracentesis. Unfortunately, the benefit of this procedure is usually short lived, with most effusions accumulating again within one month." This limits its usefulness for the acute relief of symptoms or as a component of instillational sclerotherapy.
Between these two extremes are several methods that have been advocated to control malignant pleural effusions. Older methods, such as external radiotherapy and instillation of radiocolloids or of non-sclerosant cytotoxic agents, have been largely abandoned, because of either lack of efficacy or excessive toxicity,3 although mediastinal radiotherapy may be effective in the treatment of effusions in lymphoma patients."I
The most commonly used means of treating malignant pleural effusions is drainage followed by instillation of a "sclerosant" agent. The aim of this procedure is to induce a chemical pleuritis, which as it resolves forms a symphysis between the two pleural surfaces, obliterating the pleural space and preventing reaccumulation of the effusion. The method of drainage used varies, some investigators favouring needle thoracentesis and others using tube drainage.3 In two (non-randomised) studies4" the use of tube drainage resulted in results superior to those of needle aspiration, though similar results have been reported with this latter method.'2 Irrespective of the method chosen for drainage, it is probably important to drain the pleural space to dryness before instillation of the sclerosing agent, to minimise dilution of the instilled agent and aid in the apposition of the pleural surfaces. '3 A wide range of "sclerosants" have been used after drainage, including tetracycline, bleomycin, quinacrine, nitrogen mustard, adriamycin, and talc. Recently, mitoxantrone has been reported as being useful in this setting. '4 There have been few randomised trials comparing any of these agents. Bayly et al reported that tetracycline was as effective as quinacrine and had fewer side effects.'2 In another randomised study,"' comparing adriamycin, tetracycline, and nitrogen mustard, little difference was found between adriamycin and tetracycline for control of pleural effusions, though both were more effective than nitrogen mustard. Tetracycline, however, had the lowest incidence of side effects. Hausheer and Yarbro3 imposed response criteria retrospectively on several trials of instillation treatment. They concluded that talc was probably the most effective sclerosant but that this was offset by greater morbidity than with other agents, making it unsuitable as first line treatment. Tetracycline (15 mg/kg or 1 g) and bleomycin (1 -25 mg/kg, not to exceed 40 mg in the elderly) were recommended, control of effusions being expected in 700`and 85% of cases for one month. Quinacrine, though possibly more effective than these agents, has the major drawbacks of increased toxicity and the necessity of multiple administrations.
Treatment using biological agents has also been reported.""'8 Corynebacterium parvum has been reported to be more effective than nitrogen mustard in a randomised trial, '6 Future investigation requires the adoption of a standard set of response criteria, such as those used by Hausheer and Yarbro,3 so that some comparison may be made between series. In addition, measures of quality of life should be included in the assessment oftreatment outcome, as this is a palliative procedure. There is an urgent need for prospective, randomised studies comparing different forms of treatment on the basis of relevant end points, rather than further large reviews of individual clinicians' experience. 
